Note: This document contains side effect information about ceftazidime. Some of the dosage forms listed on this page may not apply to the brand name Tazicef.
Applies to ceftazidime: injection powder for solution
Along with its needed effects, ceftazidime (the active ingredient contained in Tazicef) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking ceftazidime:
Incidence not known
Some side effects of ceftazidime may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to ceftazidime: injectable powder for injection, intravenous powder for injection, intravenous solution
Common (1% to 10%): Transient elevations in 1 or more liver enzymes (alkaline dehydrogenase, ALT, AST, GGT)
Very rare (less than 0.01%): Jaundice
Postmarketing reports: Cholestasis, hyperbilirubinemia, liver dysfunction
Common (1% to 10%): Inflammation, pain, phlebitis, thrombophlebitis
Frequency not reported: Superficial desquamation around injection site
Inflammation and pain occurred after IM administration.
Phlebitis and thrombophlebitis occurred with IV administration.
Approximately 5% of patients developed a positive Coombs test.
Common (1% to 10%): Eosinophilia, positive Coombs test, thrombocytosis
Uncommon (0.1% to 1%): Leukopenia, neutropenia, thrombocytopenia
Frequency not reported: Agranulocytosis, hemolytic anemia, lymphocytosis, positive Coombs test without hemolysis
Postmarketing reports: Aplastic anemia, pancytopenia, prothrombin time prolonged
Common (1% to 10%): Maculopapular rash, rash, urticarial rash
Uncommon (0.1% to 1%): Pruritus
Very rare (less than 0.01%): Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis
Frequency not reported: Drug reaction with eosinophilia and systemic symptoms (DRESS)
Postmarketing reports: Urticaria
Pseudomembranous colitis may have been presented as diarrhea or colitis.
Common (1% to 10%): Diarrhea
Uncommon (0.1% to 1%): Abdominal pain, antibacterial agent-associated colitis/diarrhea, colitis, nausea, vomiting
Frequency not reported: Pseudomembranous colitis
Common (1% to 10%): Transient elevations in LDH
Postmarketing reports: False-positive test for urinary glucose
Uncommon (0.1% to 1%): Transient elevations of blood urea/blood urea nitrogen (BUN)/serum creatinine
Very rare (less than 0.01%): Acute renal failure, interstitial nephritis
Postmarketing reports: Renal dysfunction, toxic nephropathy
Neurological sequelae occurred in patients with renal dysfunction who did not receive appropriate dose adjustments and included coma, convulsions, encephalopathy, myoclonia, and tremor.
Uncommon (0.1% to 1%): Dizziness, headache
Very rare (less than 0.01%): Bad taste, paresthesia,
Frequency not reported: Asterixis, coma, convulsions, encephalopathy, myoclonia, neurological sequelae, neuromuscular excitability, seizures, tremor
Uncommon (0.1% to 1%): Candidiasis, oral thrush
Uncommon (0.1% to 1%): Vaginitis
Uncommon (0.1% to 1%): Fever
Very rare (less than 0.01%): Anaphylaxis, angioedema
Postmarketing reports: Allergic reactions
Anaphylaxis included bronchospasm, cardiopulmonary arrest, and/or hypotension.
Very rare (less than 0.01%): Hypotension
Frequency not reported: Hot flushes
Postmarketing reports: Cardiopulmonary arrest, hemorrhage
Very rare (less than 0.01%): Bronchospasm
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Tazicef (www.drugs.com/mtm/tazicef.html).
March 27, 2020
March 27, 2020
March 28, 2020
March 27, 2020
March 24, 2020
March 26, 2020